ASA 81mg vs ASA 325mg: Number of Participants Experiencing Hospitalization for Nonfatal Stroke
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0137 | 0.0113 | 0.0166 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0126 | 0.0102 | 0.0154 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.00117 | -0.00253 | 0.00488 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.09 | 0.826 | 1.45 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.09 | 0.824 | 1.45 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on ASA 81mg than on ASA 325mg | 855 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | ASA 81mg | aspirin 81mg~aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily | 102 | 7,434 | OG000 | ClinicalTrials.gov |
| Group 2 | ASA 325mg | aspirin 325mg~aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily | 92 | 7,330 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Participants Experiencing Hospitalization for Nonfatal Stroke | ClinicalTrials.gov |
| Description | ClinicalTrials.gov | |
| Time frame | Time of randomization through study completion, approximately 4 years | ClinicalTrials.gov |
| Population | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term | ClinicalTrials.gov |
| NCT number | NCT02697916 | ClinicalTrials.gov |
| Phases | NA | ClinicalTrials.gov |
| Conditions | Atherosclerotic Cardiovascular Disease | ClinicalTrials.gov |
| Interventions | aspirin | ClinicalTrials.gov |
| Lead sponsor | Duke University | ClinicalTrials.gov |
| Results first posted | 2021-07-01 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT02697916?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.